Joanna Opalińska - Concepedia

Author

Joanna Opalińska

Also Known As

J. Opalinska, J. Opalinska, J. Opalińska, Joanna M. Opalinska, Joanna Opalinska, Joanna Opalinska, PhD, Joanna Opalińska

Publications

800

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park Foundation Providence College University Medical Center Hamburg-Eppendorf University of Maryland, Baltimore

About

Joanna Opalińska is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	198
2	Immunology	4	4	85
3	Health Sciences	3	3	152
4	Pathology	2	2	46
5	Nephrology	1	1	17

Joanna Opalińska

Publications

690

Citations

H-Index

Page 1

	Year	Citations
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study Sagar Lonial, Hans C. Lee, Ashraf Badros, Cancer	2021	140
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma Vânia Hungria, Paweł Robak, Marek Hus, New England Journal of Medicine	2024	127
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma Meletios Α. Dimopoulos, Meral Beksac, Luděk Pour, New England Journal of Medicine	2024	122
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study Meletios Α. Dimopoulos, Vânia Hungria, Atanas Radinoff, The Lancet Haematology Hematological MalignancyOncologyMetronomic TherapyHematologyClinical Trials	2023	113
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma Amanda Bruno, Jenny Willson, Joanna Opalińska, Expert Review of Hematology	2020	40
Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-hodgkin's lymphoma Tadeusz Robak, Joanna Góra‐Tybor, E Krykowski, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyLymphoid Neoplasia2-Cda TreatmentMedicineMalignant Blood Disorder	1997	29
Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Katja Weisel, Thomas G. Hopkins, Doug Fecteau, Blood	2019	29
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). Sagar Lonial, Hans Chulhee Lee, Ashraf Badros, Journal of Clinical Oncology ImmunologyImmune RegulationImmunoeditingPharmacotherapyImmunotherapeutics	2020	27
Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma Geraldine Ferron‐Brady, Chetan Rathi, Jon Collins, Clinical Pharmacology & Therapeutics	2021	22
DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment. Hans Chulhee Lee, Adam D. Cohen, Ajai Chari, Journal of Clinical Oncology Renal PathologyImmunologyRenal InflammationPathologyPharmacotherapy	2020	17

Page 1